What is AVAVA?
AVAVA operates at the intersection of advanced dermatology and artificial intelligence, developing sophisticated laser systems that provide clinicians with unprecedented precision. Its core offering, the MIRIA platform, represents a significant leap forward in cosmetic dermatology, utilizing AI-assisted skin imaging to guide treatment protocols. By integrating diagnostic intelligence with therapeutic laser delivery, AVAVA enables practitioners to achieve more predictable, patient-specific outcomes. The company occupies a high-growth niche within the broader medical aesthetics industry, where the demand for non-invasive, technology-backed cosmetic procedures continues to rise among both providers and patients seeking reliable, evidence-based results.
How much funding has AVAVA raised?
AVAVA has raised a total of $54.6M across 3 funding rounds:
Other Financing Round
$10M
Series C
$25M
Private Equity
$19.6M
Series C (2024): $25M with participation from Jeisys Medical
Other Financing Round (2024): $10M led by Catalio Capital Management
Private Equity (2026): $19.6M, investors not publicly disclosed
Key Investors in AVAVA
Jeisys Medical
Jeisys is a leading K-beauty medical technology company specializing in advanced RF and energy-based aesthetic devices designed for providers. With 25 years of innovation, they focus on delivering predictable outcomes and enhanced patient experiences through hands-on training and real-time support.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets. The firm focuses on breakthrough biomedical technology companies and leverages a network of venture partners to build category-defining businesses.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for AVAVA?
With the recent influx of capital, AVAVA is poised to expand its commercial footprint and deepen its R&D capabilities. The strategic focus will likely center on increasing the market penetration of the MIRIA system, particularly in the U.S. and international aesthetic markets where demand for high-tech dermatology solutions is surging. Furthermore, the company is expected to utilize these funds to enhance its AI-assisted imaging software, potentially broadening its application to new dermatological indications. As AVAVA scales, the integration of its technology into standard clinical workflows will be a key performance indicator, as will the continued development of its pipeline of energy-based aesthetic devices. The backing from specialized healthcare investors suggests a long-term vision focused on establishing AVAVA as a category-defining leader in the medical aesthetics space.
See full AVAVA company page
